by synergycap1 | Apr 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
(Reuters) – U.S. media group Meredith Corp has made a preliminary acquisition offer to Time Inc that fell short of the price expectations of the publisher of Sports Illustrated and Fortune magazines, according to people familiar with the matter.
by synergycap1 | Apr 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
The accounting firm said the employees had been terminated after it learned they were receiving improper warnings of planned audit inspections.
by synergycap1 | Apr 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
The accounting firm said the employees had been terminated after it learned they were receiving improper warnings of planned audit inspections.
by synergycap1 | Apr 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Despite the never-ending debate on the question of the role of government in America, there’s been a strong tradition of protecting our undisputed, important natural treasures, or taking on great common engineering challenges. Few Americans oppose the policies...
by synergycap1 | Apr 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
By REUTERS April 12, 2017 (Reuters) – U.S. stocks opened slightly lower on Wednesday amid lingering geopolitical risks and as investors braced for the first rush of corporate earnings, starting Thursday. The United States launched missiles at a Syrian...
by synergycap1 | Apr 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital
Shares of Neurocrine Biosciences leaped more than 22 percent Wednesday after the biotech firm announced federal approval of its drug for a movement disorder. Neurocrine announced late Tuesday that the Food and Drug Administration has approved Ingrezza, the only...
